Key result
TAVI yields similar 3-year excellent health status vs SAVR in younger, low-risk aortic stenosis.
Why the study?
Although TAVI and SAVR show non-inferior clinical outcomes in low surgical risk patients, information on the health status achieved by younger low-risk patients is lacking.
Does TAVI improve excellent health status compared to SAVR in younger, low-risk patients with aortic stenosis?
RCT (n=370)
randomised
Does TAVI improve excellent health status compared to SAVR in younger, low-risk patients with aortic stenosis?
In younger, low-risk patients with aortic stenosis, TAVI and SAVR result in comparable rates of excellent health status and safety at 3 years.
Answers are grounded in this paper and cite their sources.
Health status equivalence at 3 years informs valve selection in younger low-risk AS; extends short-term data but leaves practice change open pending RCTs.
Background Several trials have shown that transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) yield non-inferior short- and mid-term clinical outcomes in low surgical risk patients. However, information on the health status achieved by these patients is lacking. Aims To compare the incidence of excellent health status after TAVI versus SAVR in younger, low-risk patients at three-year follow-up. Methods Aortic stenosis (AS) patients aged 60-75 years with low surgical risk (n=370) were randomised to TAVI or SAVR. For this pre-defined NOTION-2 analysis, the primary safety endpoint was freedom from all-cause mortality and disabling stroke at 3 years. The primary efficacy endpoint was excellent health status, defined as Kansas City Cardiomyopathy Questionnaire (KCCQ) score >90 and New York Heart Association (NYHA) class I at three years. Results Three-year follow-up data were available for 341 patients, with health status missing in 4.3% of SAVR and 1.6% of TAVI patients. The primary safety and efficacy endpoints were comparable between TAVI and SAVR (94.6% vs. 95.1%, p=0.9; and 50.0% vs. 45.0%, p=0.35, respectively). Among patients with chronic lung disease, bicuspid AS, coronary artery disease, reduced left ventricular systolic function, or prior stroke, non-significant trends suggested a better health status following TAVI, with % risk differences of +10.5%, +13.9%, +16.0%, +18.9%, and +19.7%, respectively; however, these differences did not reach statistical significance. Conclusions After three years, half of AS patients achieved excellent health status, regardless of TAVI or SAVR. Nonetheless, certain comorbidities predict less improvement in health status, particularly following SAVR. Clinical Trial Registration: ClinicalTrials.gov Identifier NCT02825134
No takes yet. Share an insight, caveat, or question.
Phoksiri et al. (2026) conducted an RCT in Aortic stenosis (n=370). Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement (SAVR) was evaluated on Excellent health status (KCCQ score >90 and NYHA class I) at three years (p=0.35). TAVI yielded a similar incidence of excellent health status at 3 years compared to SAVR in younger, low-risk patients with aortic stenosis.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: